U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C47H51NO14
Molecular Weight 853.9061
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PACLITAXEL

SMILES

[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7

InChI

InChIKey=RCINICONZNJXQF-MZXODVADSA-N
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf and https://www.ncbi.nlm.nih.gov/pubmed/18068131

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. Taxol is marketed for the treatment of Breast cancer; Gastric cancer; Kaposi's sarcoma; Non-small cell lung cancer; Ovarian cancer. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer. Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

CNS Activity

Curator's Comment: No or negligible penetration of paclitaxel over an intact blood– brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: HeLa cell growth
7.08 µM [IC50]
Target ID: SKOV3 breast cancer cell growth
38.7 nM [IC50]
23.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TAXOL

Approved Use

TAXOL is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary.

Launch Date

8.9907842E11
Primary
TAXOL

Approved Use

TAXOL is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.

Launch Date

8.9907842E11
Primary
TAXOL

Approved Use

TAXOL, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.

Launch Date

8.9907842E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.92 μM
250 mg/m² steady-state, intravenous
dose: 250 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
PACLITAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.5 μM
175 mg/m² steady-state, intravenous
dose: 175 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
PACLITAXEL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
27.07 μM × h
250 mg/m² steady-state, intravenous
dose: 250 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
PACLITAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.8 h
175 mg/m² steady-state, intravenous
dose: 175 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
PACLITAXEL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6.5%
PACLITAXEL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Other AEs: Anaphylaxis, Dyspnea...
Other AEs:
Anaphylaxis (2%)
Dyspnea (severe, 2%)
Hypotension (severe, 2%)
Generalized urticaria (severe, 2%)
Angioedema (severe, 2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anaphylaxis 2%
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Angioedema severe, 2%
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Dyspnea severe, 2%
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Generalized urticaria severe, 2%
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Hypotension severe, 2%
135 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 135 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 135 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
Biochemical properties of a minimal functional domain with ATP-binding activity of the NTPase/helicase of hepatitis C virus.
1999 Dec
Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.
1999 Dec
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
1999 Feb
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.
1999 Mar
Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells.
1999 Mar 19
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
1999 Nov
Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel.
1999 Oct
Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine and taxol--in vitro explant study.
1999 Oct 22
Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis.
2000 Apr
Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule.
2000 Apr
Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity.
2000 Apr
Microtubules, but not actin filaments, drive daughter cell budding and cell division in Toxoplasma gondii.
2000 Apr
Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study.
2000 Aug
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
2000 Aug
Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
2000 Dec 1
Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
2000 Jan
Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol.
2000 Jan 28
Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.
2000 Jul 1
Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels.
2000 Jun
Biochemical mechanism of cross-resistance to paclitaxel in a mitomycin c-resistant human bladder cancer cell line.
2000 Mar 31
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
2000 May
Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer.
2000 May-Jun
Cell cycle status and apoptosis of hematopoietic progenitor cells released into the peripheral blood after taxanes and granulocyte colony-stimulating factor in breast cancer patients.
2000 May-Jun
Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.
2000 Sep
A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: a prospective study in patients with ovarian cancer.
2000 Sep-Oct
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
2001
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
2001
In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry.
2001
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.
2001 Apr
Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition.
2001 Apr 26
Phytochemistry and medicinal plants.
2001 Feb
Selective drug resistant human osteosarcoma cell lines.
2001 Feb
Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells.
2001 Feb
Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.
2001 Jan
Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation.
2001 Jan
Colchicine and griseofulvin inhibit VCAM-1 expression on human vascular endothelial cells - evidence for the association of VCAM-1 expression with microtubules.
2001 Jan
Opposite effects of microtubule-stabilizing and microtubule-destabilizing drugs on biogenesis of mitochondria in mammalian cells.
2001 Jan
Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers.
2001 Jan
CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression.
2001 Jan 1
Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
2001 Jan 15
Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity.
2001 Jan 15
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
2001 Jan 15
Dispersion of cyclin B mRNA aggregation is coupled with translational activation of the mRNA during zebrafish oocyte maturation.
2001 Jan 15
The role of actin filaments and microtubules in hepatocyte spheroid self-assembly.
2001 Mar
Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.
2001 Mar 1
Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers.
2001 Mar 12
Patents

Sample Use Guides

For previously untreated patients with carcinoma of the ovary, one of the following recommended regimens may be given every 3 weeks. a.TAXOL (PACLITAXEL) administered intravenously over 3 hours at a dose of 175 mg/m2 followed by cisplatin at a dose of 75 mg/m2; or b.TAXOL (PACLITAXEL) administered intravenously over 24 hours at a dose of 135 mg/m2 followed by cisplatin at a dose of 75 mg/m2 2) In patients previously treated with chemotherapy for carcinoma of the ovary, the recommended regimen is TAXOL (PACLITAXEL) 135 mg/m2 or 175 mg/m2 administered intravenously over 3 hours every 3 weeks.
Route of Administration: Intravenous
Paclitaxel inhibited tubulin polymerization in the presence of MAPs in vitro with an IC50 value of 38.19 ± 3.33 uM in living cancer cells (Hela cells and human osteosarcoma U2OS cells).
Name Type Language
PACLITAXEL
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
ONCOGEL
Common Name English
PACLITAXEL [MART.]
Common Name English
EBETAXEL
Common Name English
PAXENE
Brand Name English
NSC-125973
Code English
INTAXEL
Common Name English
TAXOL
Brand Name English
PACLITAXEL [USAN]
Common Name English
MITOTAX
Common Name English
ABI-007 COMPONENT PACLITAXEL
Code English
PACLITAXEL [USP-RS]
Common Name English
BMS-181339-01
Code English
NAB-PACLITAXEL COMPONENT PACLITAXEL
Common Name English
ONXAL
Common Name English
GENETAXYL
Common Name English
MBT-0206
Code English
NK-105
Code English
PACLITAXEL [ORANGE BOOK]
Common Name English
BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,
Systematic Name English
DHP-107
Code English
CAPXOL
Common Name English
PACLITAXEL [MI]
Common Name English
ORAXOL COMPONENT PACLITAXEL
Common Name English
PACLITAXEL [VANDF]
Common Name English
GENEXOL
Brand Name English
PACLITAXEL [GREEN BOOK]
Common Name English
Paclitaxel [WHO-DD]
Common Name English
EMPAC
Common Name English
PLAXICEL
Common Name English
GENEXOL-PM
Common Name English
ABI 007 COMPONENT PACLITAXEL
Common Name English
TAXUS
Common Name English
PACLITAXEL [EP MONOGRAPH]
Common Name English
PACLIEX
Common Name English
ENDOTAG 1
Common Name English
(-)-PACLITAXEL
Common Name English
PACLITAXEL [USP MONOGRAPH]
Common Name English
LIPOSOME-ENTRAPPED PACLITAXEL EASY-TO-USE
Common Name English
TAXOL A
Common Name English
PACLITAXEL (TAXUS CANADENSIS)
Common Name English
ABRAXANE COMPONENT PACLITAXEL
Brand Name English
PACLITAXEL [EMA EPAR]
Common Name English
paclitaxel [INN]
Common Name English
GENAXOL
Common Name English
PACLITAXEL [JAN]
Common Name English
TAXALBIN
Common Name English
YEWTAXAN
Brand Name English
PACLITAXEL [USP IMPURITY]
Common Name English
CYCLOPAX
Common Name English
PACLITAXOL
Common Name English
LEP-ETU
Common Name English
TAXUS STENT
Common Name English
ZISU
Brand Name English
TOCOSOL PACLITAXEL
Common Name English
QW-8184
Code English
PACLITAXEL [HSDB]
Common Name English
ONXOL
Brand Name English
TAXUS LIBERTE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 270208
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 50190
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
NDF-RT N0000175085
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
LIVERTOX NBK548093
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 394813
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
NCI_THESAURUS C67437
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
EU-Orphan Drug EU/3/06/422
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 454014
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
WHO-VATC QL01CD01
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 594217
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 469915
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 103497
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 186404
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 482015
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
NDF-RT N0000175592
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 278309
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 384912
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 104797
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 454114
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
EMA ASSESSMENT REPORTS PAXENE (WITHDRAWN: OVARIAN NEOPLASMS)
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
CFR 21 CFR 516.1684
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 290709
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 252907
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
NCI_THESAURUS C1490
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
WHO-ATC L01CD01
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
EMA ASSESSMENT REPORTS ABRAXANE (AUTHORIZED: PANCREATIC NEOPLASMS)
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 291009
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
EMA ASSESSMENT REPORTS PAXENE (WITHDRAWN: CARCINOMA, NON-SMALL-CELL LUNG)
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 141701
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
FDA ORPHAN DRUG 280409
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
Code System Code Type Description
CAS
33069-62-4
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
SMS_ID
100000085474
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
DAILYMED
P88XT4IS4D
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
USAN
EE-62
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
CHEBI
45863
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
MESH
D017239
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
HSDB
6839
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
NSC
125973
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
ChEMBL
CHEMBL428647
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
EPA CompTox
DTXSID9023413
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
DRUG BANK
DB01229
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
IUPHAR
2770
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
FDA UNII
P88XT4IS4D
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
INN
7052
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
WIKIPEDIA
PACLITAXEL
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
RS_ITEM_NUM
1491332
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
RXCUI
56946
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
EVMPD
SUB09583MIG
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
NCI_THESAURUS
C1411
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
PUBCHEM
36314
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
MERCK INDEX
M8351
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY Merck Index
LACTMED
Paclitaxel
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
MESH
C495179
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
DRUG CENTRAL
2044
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
PRIMARY
RXCUI
486610
Created by admin on Wed Jul 05 22:49:38 UTC 2023 , Edited by admin on Wed Jul 05 22:49:38 UTC 2023
ALTERNATIVE